IAR025, a novel anti-DLL3 x CD3-bispecific antibody, displays high antitumor efficacy in preclinical models of small-cell lung cancer

Abstract Small-cell lung cancer (SCLC) is one of the most aggressive subtype of lung carcinoma with limited treatment options. Delta-like ligand 3 (DLL3), a Notch ligand protein, has been an attractive target for SCLC due to its high expression on SCLC but limited expression on normal tissues. Here,...

Full beskrivning

Bibliografiska uppgifter

Huvudupphov:	Yang Liu, Lei Cao, Mengqiu Xu, Ninghuan Li, Jian Zhang, Mengjia Zhu, Zhihui Kuang, Huijun Sha, Min Wu, Jinling Xu, Zhihai Wu, Ye Feng, Li Li
Materialtyp:	Artigo
Språk:	Inglês
Utgiven:	Springer 2026-05-01
Serie:	Cancer Immunology, Immunotherapy
Ämnen:	DLL3 T-cell engager Bispecific antibody Small-cell lung cancer Combination therapy
Länkar:	https://doi.org/10.1007/s00262-026-04416-w
Taggar:	Lägg till en tagg Inga taggar, Lägg till första taggen!